A Phase 3 interventional study of Tolvaptan Oral Tablet in Syndrome of Inappropriate Antidiuretic Hormone Secretion, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 6 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-11-02.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Inappropriate ADH Syndrome · Otsuka Holdings Co., Ltd..
Among the 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd., this one is the only one that started in 2017, is one of 4 in phase 3, and was the 9th registered.
41 studies on the registry are indexed under Inappropriate ADH Syndrome; 3 are open to participants now.
Browse Inappropriate ADH Syndrome studies →None of the 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd. is open now. The open studies under Inappropriate ADH Syndrome, anywhere →
Of the 3 Inappropriate ADH Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2017.
This study's enrollment of 16 is below the median of 36 across 24 interventional studies indexed under Inappropriate ADH Syndrome.
Median enrollment 124 across the 5 interventional studies, 100 across the 5 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to investigate the efficacy and safety of tolvaptan based on the change in serum sodium concentration following administration of tolvaptan oral tablets at 7.5 to 60 mg/day for up to 30 days in patients with hyponatremia in the SIADH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
Drug: Tolvaptan Oral Tablet
Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration
The percentage of subjects with normalized serum sodium concentration, defined as ≥135 mEq/L, on the day after final IMP administration will be calculated versus the number of subjects with serum sodium concentration of \<135 mEq/L at baseline on Day 1 of the treatment period.
Time frame: Baseline, Day2, Day3, Day4, Day5, Day7, Day14, Day21, Day after final study medication
Change in Serum Sodium Concentration
The mean and standard error of measured values for serum sodium concentration on the day of fixing the maintenance dose and on the day after final IMP administration were calculated. The day of fixing the maintenance dose: Day2, Day3, Day4, Day5, Day7, Day14, and Day21
Time frame: Day2, Day3, Day4, Day5, Day7, Day14, Day21 and the day after final IMP administration
This trial was conducted in 16 participants from 31 trial sites in Japan.
| Milestone | Tolvaptan |
|---|---|
| Started | 16 |
| Completed | 11 |
| Not completed | 5 |
| Withdrew: Adverse event | 2 |
| Withdrew: Participant met withdrawal criteria | 2 |
| Withdrew: Physician decision | 1 |
The percentage of subjects with normalized serum sodium concentration, defined as ≥135 mEq/L, on the day after final IMP administration will be calculated versus the number of subjects with serum sodium concentration of \<135 mEq/L at baseline on Day 1 of the treatment period.
| percentage of participants | Tolvaptan |
|---|---|
| Day2 | 43.8 |
| Day3 | 80 |
| Day4 | 80 |
| Day5 | 85.7 |
| Day7 | 92.9 |
| Day14 | 83.3 |
| Day21 | 81.8 |
| Day after final study medication | 81.3 |
The mean and standard error of measured values for serum sodium concentration on the day of fixing the maintenance dose and on the day after final IMP administration were calculated. The day of fixing the maintenance dose: Day2, Day3, Day4, Day5, Day7, Day14, and Day21
| mEq/L | Tolvaptan |
|---|---|
| Day2 | 6.9 ± 2.6 |
| Day3 | 8.1 ± 3.8 |
| Day4 | 8.5 ± 4.6 |
| Day5 | 8.8 ± 4.4 |
| Day7 | 10.0 ± 4.5 |
| Day14 | 10.8 ± 3.7 |
| Day21 | 10.4 ± 6.0 |
| Day after final study medication | 11.0 ± 4.3 |
Collected over Adverse events were monitored from signing of the informed consent form until follow-up, up to 7 weeks on average.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan | 1/16 (6.3%) | 5/16 (31.3%) | 15/16 (93.8%) |
| Event | Tolvaptan |
|---|---|
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/16 |
| Supraventricular extrasystolesCardiac disorders | 1/16 |
| Ventricular extrasystolesCardiac disorders | 1/16 |
| BacteraemiaInfections and infestations | 1/16 |
| Back painMusculoskeletal and connective tissue disorders | 1/16 |
| Loss of consciousnessNervous system disorders | 1/16 |
| Paralysis of recurrent laryngeal nerveNervous system disorders | 1/16 |
| Circulatory collapseVascular disorders | 1/16 |
| HaemorrhageVascular disorders | 1/16 |
| Event | Tolvaptan |
|---|---|
| ThirstGeneral disorders | 3/16 |
| Decreased appetiteMetabolism and nutrition disorders | 3/16 |
| NeutropeniaBlood and lymphatic system disorders | 2/16 |
| ConstipationGastrointestinal disorders | 2/16 |
| NauseaGastrointestinal disorders | 2/16 |
| VomitingGastrointestinal disorders | 2/16 |
| PyrexiaGeneral disorders | 2/16 |
| GingivitisInfections and infestations | 2/16 |
| FallInjury, poisoning and procedural complications | 2/16 |
| Blood creatinine increasedInvestigations | 2/16 |
Safety analysis set, which included in patients who received ≥1 dose of the study medication.
| Age, Categorical(Participants) | Tolvaptan |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1 |
| >=65 years | 15 |
| Age, Continuous(years) | Tolvaptan |
|---|---|
| Mean | 71.9 ± 6.1 |
| Sex: Female, Male(Participants) | Tolvaptan |
|---|---|
| Female | 3 |
| Male | 13 |
| Race/Ethnicity, Customized(Participants) | Tolvaptan |
|---|---|
| Japanese | 16 |
| Region of Enrollment(participants) | Tolvaptan |
|---|---|
| Japan | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Supporting Materials: Study Protocol and Statistical Analysis Plan (SAP) Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data. Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available aftermarketing approval in global markets, or beginning1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and Ranalytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from Mar 2017 to primary completion in Mar 2019, 24 months.
Results were first posted in Nov 2020, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Co., Ltd. →